查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1363066

视网膜静脉阻塞治疗的市场规模、份额和趋势分析报告：按最终用户、疾病类型、治疗方法方法、地区、细分趋势，2023-2030

Retinal Vein Occlusion Treatment Market Size, Share & Trends Analysis Report By End-user (Retail Pharmacy, Hospital & Clinics), By Disease Type (CRVO, BRVO), By Treatment (Anti-VEGF, Corticosteroid Drugs), By Region, & Segment Forecasts, 2023 - 2030
出版日期: | 出版商: Grand View Research | 英文 180 Pages | 商品交期: 2-10个工作天内

价格

视网膜静脉阻塞治疗市场的成长与趋势：

根据Grand View Research, Inc.最新报告，预计到2030年，全球视网膜静脉阻塞治疗市场规模将达41.8亿美元，2023年至2030年年复合成长率为6.92%。

眼科疾病患病的增加、老年人口的增加、对眼科疾病治疗意识的增强是推动市场成长的主要要素。现有和已通过核准产品的存在以及强大的产品平臺是预计推动市场成长的要素。此外，糖尿病和动脉粥状硬化患病的增加可能会增加 RVO 的患病，从而对研究期间的市场产生积极影响。 RVO 新药核准数量的增加预计将在研究期间为市场提供利润丰厚的机会。

三星Bioepis开发了首个生物相似药Byooviz（ranibizumab-nuna），用于治疗黄斑部水肿、新生血管老龄化黄斑部病变、近视脉络膜新生血管和RVO等视网膜疾病。 2020年9月，该药物获得FDA商业化核准。然而，与药物相关的高成本可能会限制其处方并阻碍市场成长。根据《BMC 眼科》 2021 年发表的一项研究，在中国，用雷珠单抗治疗中央RVO (CRVO) 和分支RVO (BRVO) 的费用约为每个质量调整生命年(QALY) 449.17 美元和454.75美元。因此，高效、安全的廉价药物的推出预计将在预测期内为市场带来新的成长机会。

此外，糖尿病视网膜病变、白内障、青光眼和老龄化黄斑部病变等疾病是全世界这种疾病的主要原因。老年人口的增加相应地增加了受 RVO罹患的人数。此外，生活方式的改变也增加了导致RVO的各种疾病的发生率，例如心血管疾病和高血压。根据《刺胳针》全球卫生委员会关于全球眼健康的报告，2020年全球将有5.1亿人出现未矫正的近距离视力丧失，其中5.96亿人出现未矫正的近距离视力丧失，估计有100万人患有未矫正的远视力障碍。因此，继发性疾病患病的增加可能会增加 RVO 的患病并支持市场成长。

视网膜静脉阻塞治疗市场报告亮点

  • 按疾病类型划分，由于研发活动和新药开发投资的增加，以实现高效治疗，分支细分市场在 2022 年占据市场主导地位。
  • 从治疗药物来看，抗血管内皮生长因子药物（抗VEGF药物）由于其安全性和第一线药物的普遍接受性，在2022年占据最大的市场份额。
  • 由于药品供应量的提高以及透过零售药局提供的 RVO 选项等要素，零售药局最终用户细分市场在 2022 年占据最大份额。
  • 北美地区到 2022 年将占据 41.2% 的份额，确立了按地区分類的强势地位。这是广泛的研究和开发活动以及由于该地区政府资助增加而导致的高治疗方法采用率的结果。

目录

第1章调查方法和范围

第2章执行摘要

第3章市场变数、趋势和范围

  • 市场区隔和范围
  • 市场体系预测
    • 母市场预测
    • 相关/附随市场预测
  • 市场动态
  • 市场促进因素
    • 视网膜疾病患病增加
    • 老年人口增加
    • 拥有强大的产品系列
  • 市场抑制因素分析
    • 对疾病缺乏认识与诊断不足
    • 治疗费用高
  • 营商环境分析
    • SWOT 分析；要素因素（政治/法律、经济/技术）
    • 波特五力分析
    • COVID-19感染疾病的影响分析

第4章疾病业务分析

  • 视网膜静脉阻塞治疗市场：疾病类型变异分析
  • 视网膜中央静脉阻塞（CRVO）
  • 视网膜分支静脉阻塞症（BRVO）

第5章业务分析（依处理方式）

  • 视网膜静脉阻塞治疗市场：治疗变异分析
  • 抗血管内皮生长因子（抗VEGF）
  • 皮质类固醇药物
  • 其他的

第6章最终使用者的业务分析

  • 视网膜静脉阻塞治疗市场：最终用户变化分析
  • 医院和诊所
  • 零售药房
  • 其他的

第7章区域业务分析

  • 2022年及2030年视网膜静脉阻塞治疗按地区市场占有率
  • 北美洲
  • 欧洲
  • 亚太地区
  • 拉丁美洲
  • 中东/非洲

第8章竞争形势

  • 参与企业概况
  • 财务实绩
  • 参与企业
Product Code: GVR-4-68040-122-1

Retinal Vein OcclusionTreatment Market Growth & Trends:

The global retinal vein occlusion treatment market size is expected to reach USD 4.18 billion by 2030, growingat a CAGR of 6.92% from 2023 to 2030, according to a new report by Grand View Research, Inc.. Growing prevalence of eye diseases, increasing geriatric population, coupled with rising awareness about ophthalmic disease treatment are the key factors boosting the market growth. The presence of already existing products or approved products and a strong product pipeline are factors anticipated to fuel the market growth. Furthermore, the increasing prevalence of diabetes and atherosclerosis may increase the prevalence of RVO and positively impact the market during the study period. Rising approval of novel drugs for RVO is expected to offer lucrative opportunities for the market during the study period.

Samsung Bioepis developed the first biosimilar drug Byooviz (ranibizumab-nuna) for the treatment of retinal disorders, such as macular edema, neovascular age-related macular degeneration, myopic choroidal neovascularization, and RVO. In September 2020, the drug was approved by the FDA for commercialization. However, the high cost associated with drugs may limit the prescription of drugs and hinder market growth. According to a 2021 study published in BMC Ophthalmology, the treatment of central RVO(CRVO) and branch RVO (BRVO) with ranibizumab costs approximately USD 449.17 and USD 454.75 per quality-adjusted life year (QALY) in China. Therefore, the introduction of affordable drugs with high efficacy and safety is expected to create new growth opportunities for the market during the projected timeframe.

Moreover, conditions, such as diabetic retinopathy, cataract, glaucoma, and age-related macular degeneration, are major causes of the disorder globally. A rise in the elderly population is creating a proportionate increase in number of people suffering from RVO. In addition, lifestyle changes have also resulted in increased incidence of various diseases causing RVO, such as cardiovascular diseases & hypertension. According to the Lancet Global Health Commission's report on global eye health, it was estimated that in 2020, 510 million people worldwide had uncorrected close vision impairment, and 596 million people worldwide had uncorrected distance vision impairment. Thus, the increasing prevalence of secondary conditions may increase the prevalence of RVO and support market growth.

Retinal Vein Occlusion Treatment Market Report Highlights:

  • By disease type, the branch segment dominated themarket in 2022 owing to the increasing focus on R&D activities and investments to develop novel drugs for efficient treatment
  • By treatment, anti-vascular endothelial growth factor (Anti-VEGF) segment held the largest share in 2022 owing to their safety and universal acceptance as the first-line treatment option
  • The retail pharmacy end-user segment held the largest share in 2022 due to factors, such as improved accessibility of medication and available options for RVO through retail pharmacies
  • North America established a strong regional position with a 41.2% share in 2022. This is a result of the region's extensive R&D activities due to increased government funding and a high adoption rate of treatments

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation
    • 1.1.1. Market Definitions
  • 1.2. Objectives
    • 1.2.1. Objective - 1
    • 1.2.2. Objective - 2
    • 1.2.3. Objective - 3
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased Database
    • 1.4.2. Gvr's Internal Database
    • 1.4.3. Secondary Sources
    • 1.4.4. Primary Research
  • 1.5. Information Or Data Analysis
    • 1.5.1. Data Analysis Models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity Flow Analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Abbreviations
  • 1.10. List of Primary Sources

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Disease Type and Treatment Snapshot
  • 2.3. End-user Snapshot
  • 2.4. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Segmentation and Scope
  • 3.2. Market Lineage Outlook
    • 3.2.1. Parent Market Outlook
    • 3.2.2. Related/Ancillary Market Outlook
  • 3.3. Market Dynamics
  • 3.4. Market Drivers
    • 3.4.1. Increasing prevalence of retinal diseases
    • 3.4.2. Rising geriatric population
    • 3.4.3. Presence of strong product portfolio
  • 3.5. Market Restraint Analysis
    • 3.5.1. Lack of awareness and underdiagnoses of the disease
    • 3.5.2. High cost of the treatment
  • 3.6. Business Environment Analysis
    • 3.6.1. SWOT Analysis; By Factor (Political & Legal, Economic And Technological)
    • 3.6.2. Porter's Five Forces Analysis
    • 3.6.3. COVID-19 Impact Analysis

Chapter 4. Disease Type Business Analysis

  • 4.1. Retinal Vein Occlusion Treatment market: Disease Type Movement Analysis
  • 4.2. Central Retinal Vein Occlusion (CRVO)
    • 4.2.1. Central Retinal Vein Occlusion (CRVO) Market, 2018 - 2030 (USD Million)
  • 4.3. Branch Retinal Vein Occlusion (BRVO)
    • 4.3.1. Branch Retinal Vein Occlusion (BRVO) Market, 2018 - 2030 (USD Million)

Chapter 5. Treatment Business Analysis

  • 5.1. Retinal Vein Occlusion Treatment Market: Treatment Movement Analysis
  • 5.2. Anti-vascular Endothelial Growth Factor (Anti-VEGF)
    • 5.2.1. Anti-vascular Endothelial Growth Factor (Anti-VEGF) Market, 2018 - 2030 (USD Million)
  • 5.3. Corticosteroid Drugs
    • 5.3.1. Corticosteroid Drugs Market, 2018 - 2030 (USD Million)
  • 5.4. Others
    • 5.4.1. Others Market, 2018 - 2030 (USD Million)

Chapter 6. End-user Business Analysis

  • 6.1. Retinal Vein Occlusion Treatment Market: End-user Movement Analysis
  • 6.2. Hospital & Clinics
    • 6.2.1. Hospital & Clinics Market, 2018 - 2030 (USD Million)
  • 6.3. Retail Pharmacy
    • 6.3.1. Retail Pharmacy Market, 2018 - 2030 (USD Million)
  • 6.4. Others
    • 6.4.1. Others Market, 2018 - 2030 (USD Million)

Chapter 7. Regional Business Analysis

  • 7.1. Retinal Vein Occlusion Treatment Market Share By Region, 2022 & 2030
  • 7.2. North America
    • 7.2.1. North America Retinal Vein Occlusion Treatment market, 2018 - 2030 (USD Million)
    • 7.2.2. U.S.
      • 7.2.2.1. Key Country Dynamics
      • 7.2.2.2. Target Disease Prevalence
      • 7.2.2.3. Competitive Scenario
      • 7.2.2.4. Regulatory Framework
      • 7.2.2.5. Reimbursement Scenario
      • 7.2.2.6. U.S. Retinal Vein Occlusion Treatment market, 2018 - 2030 (USD MILLION)
    • 7.2.3. Canada
      • 7.2.3.1. Key Country Dynamics
      • 7.2.3.2. Target Disease Prevalence
      • 7.2.3.3. Competitive Scenario
      • 7.2.3.4. Regulatory Framework
      • 7.2.3.5. Reimbursement Scenario
      • 7.2.3.6. Canada Retinal Vein Occlusion Treatment market, 2018 - 2030 (USD Million)
  • 7.3. Europe
    • 7.3.1. Europe Retinal Vein Occlusion Treatment market, 2018 - 2030 (USD Million)
    • 7.3.2. Germany
      • 7.3.2.1. Key Country Dynamics
      • 7.3.2.2. Target Disease Prevalence
      • 7.3.2.3. Competitive Scenario
      • 7.3.2.4. Regulatory Framework
      • 7.3.2.5. Reimbursement Scenario
      • 7.3.2.6. Germany Retinal Vein Occlusion Treatment market, 2018 - 2030 (USD Million)
    • 7.3.3. UK
      • 7.3.3.1. Key Country Dynamics
      • 7.3.3.2. Target Disease Prevalence
      • 7.3.3.3. Competitive Scenario
      • 7.3.3.4. Regulatory Framework
      • 7.3.3.5. Reimbursement Scenario
      • 7.3.3.6. UK Retinal Vein Occlusion Treatment market, 2018 - 2030 (USD Million)
    • 7.3.4. France
      • 7.3.4.1. Key Country Dynamics
      • 7.3.4.2. Target Disease Prevalence
      • 7.3.4.3. Competitive Scenario
      • 7.3.4.4. Regulatory Framework
      • 7.3.4.5. Reimbursement Scenario
      • 7.3.4.6. France Retinal Vein Occlusion Treatment market, 2018 - 2030 (USD Million)
    • 7.3.5. Italy
      • 7.3.5.1. Key Country Dynamics
      • 7.3.5.2. Target Disease Prevalence
      • 7.3.5.3. Competitive Scenario
      • 7.3.5.4. Regulatory Framework
      • 7.3.5.5. Reimbursement Scenario
      • 7.3.5.6. Italy Retinal Vein Occlusion Treatment market, 2018 - 2030 (USD Million)
    • 7.3.6. Spain
      • 7.3.6.1. Key Country Dynamics
      • 7.3.6.2. Target Disease Prevalence
      • 7.3.6.3. Competitive Scenario
      • 7.3.6.4. Regulatory Framework
      • 7.3.6.5. Reimbursement Scenario
      • 7.3.6.6. Spain Retinal Vein Occlusion Treatment market, 2018 - 2030 (USD Million)
    • 7.3.7. Denmark
      • 7.3.7.1. Key Country Dynamics
      • 7.3.7.2. Target Disease Prevalence
      • 7.3.7.3. Competitive Scenario
      • 7.3.7.4. Regulatory Framework
      • 7.3.7.5. Reimbursement Scenario
      • 7.3.7.6. Denmark Retinal Vein Occlusion Treatment market, 2018 - 2030 (USD Million)
    • 7.3.8. Sweden
      • 7.3.8.1. Key Country Dynamics
      • 7.3.8.2. Target Disease Prevalence
      • 7.3.8.3. Competitive Scenario
      • 7.3.8.4. Regulatory Framework
      • 7.3.8.5. Reimbursement Scenario
      • 7.3.8.6. Sweden Retinal Vein Occlusion Treatment market, 2018 - 2030 (USD Million)
    • 7.3.9. Norway
      • 7.3.9.1. Key Country Dynamics
      • 7.3.9.2. Target Disease Prevalence
      • 7.3.9.3. Competitive Scenario
      • 7.3.9.4. Regulatory Framework
      • 7.3.9.5. Reimbursement Scenario
      • 7.3.9.6. Norway Retinal Vein Occlusion Treatment market, 2018 - 2030 (USD Million)
  • 7.4. Asia Pacific
    • 7.4.1. Asia Pacific Retinal Vein Occlusion Treatment market, 2018 - 2030 (USD Million)
    • 7.4.2. Japan
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Target Disease Prevalence
      • 7.4.2.3. Competitive Scenario
      • 7.4.2.4. Regulatory Framework
      • 7.4.2.5. Reimbursement Scenario
      • 7.4.2.6. Japan Retinal Vein Occlusion Treatment market, 2018 - 2030 (USD Million)
    • 7.4.3. China
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Target Disease Prevalence
      • 7.4.3.3. Competitive Scenario
      • 7.4.3.4. Regulatory Framework
      • 7.4.3.5. Reimbursement Scenario
      • 7.4.3.6. China Retinal Vein Occlusion Treatment market, 2018 - 2030 (USD Million)
    • 7.4.4. India
      • 7.4.4.1. Key Country Dynamics
      • 7.4.4.2. Target Disease Prevalence
      • 7.4.4.3. Competitive Scenario
      • 7.4.4.4. Regulatory Framework
      • 7.4.4.5. Reimbursement Scenario
      • 7.4.4.6. India Retinal Vein Occlusion Treatment market, 2018 - 2030 (USD Million)
    • 7.4.5. South Korea
      • 7.4.5.1. Key Country Dynamics
      • 7.4.5.2. Target Disease Prevalence
      • 7.4.5.3. Competitive Scenario
      • 7.4.5.4. Regulatory Framework
      • 7.4.5.5. Reimbursement Scenario
      • 7.4.5.6. South Korea Retinal Vein Occlusion Treatment market, 2018 - 2030 (USD Million)
    • 7.4.6. Australia
      • 7.4.6.1. Key Country Dynamics
      • 7.4.6.2. Target Disease Prevalence
      • 7.4.6.3. Competitive Scenario
      • 7.4.6.4. Regulatory Framework
      • 7.4.6.5. Reimbursement Scenario
      • 7.4.6.6. Australia Retinal Vein Occlusion Treatment market, 2018 - 2030 (USD Million)
    • 7.4.7. Thailand
      • 7.4.7.1. Key Country Dynamics
      • 7.4.7.2. Target Disease Prevalence
      • 7.4.7.3. Competitive Scenario
      • 7.4.7.4. Regulatory Framework
      • 7.4.7.5. Reimbursement Scenario
      • 7.4.7.6. Thailand Retinal Vein Occlusion Treatment market, 2018 - 2030 (USD Million)
  • 7.5. Latin America
    • 7.5.1. Latin America Retinal Vein Occlusion Treatment market, 2018 - 2030 (USD Million)
    • 7.5.2. Brazil
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Target Disease Prevalence
      • 7.5.2.3. Competitive Scenario
      • 7.5.2.4. Regulatory Framework
      • 7.5.2.5. Reimbursement Scenario
      • 7.5.2.6. Brazil Retinal Vein Occlusion Treatment market, 2018 - 2030 (USD Million)
    • 7.5.3. Mexico
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Target Disease Prevalence
      • 7.5.3.3. Competitive Scenario
      • 7.5.3.4. Regulatory Framework
      • 7.5.3.5. Reimbursement Scenario
      • 7.5.3.6. Mexico Retinal Vein Occlusion Treatment market, 2018 - 2030 (USD Million)
    • 7.5.4. Argentina
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Target Disease Prevalence
      • 7.5.4.3. Competitive Scenario
      • 7.5.4.4. Regulatory Framework
      • 7.5.4.5. Reimbursement Scenario
      • 7.5.4.6. Argentina Retinal Vein Occlusion Treatment market, 2018 - 2030 (USD Million)
  • 7.6. MEA
    • 7.6.1. MEA Retinal Vein Occlusion Treatment market, 2018 - 2030 (USD Million)
    • 7.6.2. South Africa
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Target Disease Prevalence
      • 7.6.2.3. Competitive Scenario
      • 7.6.2.4. Regulatory Framework
      • 7.6.2.5. Reimbursement Scenario
      • 7.6.2.6. South Africa Retinal Vein Occlusion Treatment market, 2018 - 2030 (USD Million)
    • 7.6.3. Saudi Arabia
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Target Disease Prevalence
      • 7.6.3.3. Competitive Scenario
      • 7.6.3.4. Regulatory Framework
      • 7.6.3.5. Reimbursement Scenario
      • 7.6.3.6. Saudi Arabia Retinal Vein Occlusion Treatment market, 2018 - 2030 (USD Million)
    • 7.6.4. UAE
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Target Disease Prevalence
      • 7.6.4.3. Competitive Scenario
      • 7.6.4.4. Regulatory Framework
      • 7.6.4.5. Reimbursement Scenario
      • 7.6.4.6. UAE Retinal Vein Occlusion Treatment market, 2018 - 2030 (USD Million)
    • 7.6.5. Kuwait
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Target Disease Prevalence
      • 7.6.5.3. Competitive Scenario
      • 7.6.5.4. Regulatory Framework
      • 7.6.5.5. Reimbursement Scenario
      • 7.6.5.6. Kuwait Retinal Vein Occlusion Treatment market, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Participant's overview
  • 8.2. Financial performance
  • 8.3. Participant categorization
    • 8.3.1. Market Leaders
    • 8.3.2. Retinal Vein Occlusion Treatment market Share Analysis, 2022
    • 8.3.3. Company Profiles
      • 8.3.3.1. AbbVie Inc
      • 8.3.3.1.1. Company Overview
      • 8.3.3.1.2. Financial Performance
      • 8.3.3.1.3. Product Benchmarking
      • 8.3.3.1.4. Strategic Initiatives
      • 8.3.3.2. F. Hoffmann-La Roche Ltd
      • 8.3.3.2.1. Company Overview
      • 8.3.3.2.2. Financial Performance
      • 8.3.3.2.3. Product Benchmarking
      • 8.3.3.2.4. Strategic Initiatives
      • 8.3.3.3. Regeneron Pharmaceuticals Inc
      • 8.3.3.3.1. Company Overview
      • 8.3.3.3.2. Financial Performance
      • 8.3.3.3.3. Product Benchmarking
      • 8.3.3.3.4. Strategic Initiatives
      • 8.3.3.4. Taiwan Liposome Company, Ltd
      • 8.3.3.4.1. Company Overview
      • 8.3.3.4.2. Financial Performance
      • 8.3.3.4.3. Product Benchmarking
      • 8.3.3.4.4. Strategic Initiatives
      • 8.3.3.5. Aerie Pharmaceuticals Inc
      • 8.3.3.5.1. Company Overview
      • 8.3.3.5.2. Financial Performance
      • 8.3.3.5.3. Product Benchmarking
      • 8.3.3.5.4. Strategic Initiatives
      • 8.3.3.6. CalciMedica Inc
      • 8.3.3.6.1. Company Overview
      • 8.3.3.6.2. Financial Performance
      • 8.3.3.6.3. Product Benchmarking
      • 8.3.3.6.4. Strategic Initiatives
      • 8.3.3.7. Outlook Therapeutics, Inc
      • 8.3.3.7.1. Company Overview
      • 8.3.3.7.2. Financial Performance
      • 8.3.3.7.3. Product Benchmarking
      • 8.3.3.7.4. Strategic Initiatives
      • 8.3.3.8. Kodiak Sciences Inc
      • 8.3.3.8.1. Company Overview
      • 8.3.3.8.2. Financial Performance
      • 8.3.3.8.3. Product Benchmarking
      • 8.3.3.8.4. Strategic Initiatives
      • 8.3.3.9. Chugai Pharmaceutical Co., Ltd
      • 8.3.3.9.1. Company Overview
      • 8.3.3.9.2. Financial Performance
      • 8.3.3.9.3. Product Benchmarking
      • 8.3.3.9.4. Strategic Initiatives
      • 8.3.3.10. Pfizer Inc
      • 8.3.3.10.1. Company Overview
      • 8.3.3.10.2. Financial Performance
      • 8.3.3.10.3. Product Benchmarking
      • 8.3.3.10.4. Strategic Initiatives
    • 8.3.4. Strategy Mapping
      • 8.3.4.1. Expansion
      • 8.3.4.2. Acquisition
      • 8.3.4.3. Collaborations
      • 8.3.4.4. Disease Type/Drug Class Launch
      • 8.3.4.5. Partnerships
      • 8.3.4.6. Others

List of Tables

  • Table 1 List of Abbreviations
  • Table 2 Global Retinal Vein Occlusion Treatment Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 3 Global Retinal Vein Occlusion Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 4 Global Retinal Vein Occlusion Treatment Market, by End-user, 2018 - 2030 (USD Million)
  • Table 5 Global Retinal Vein Occlusion Treatment Market, by Region, 2018 - 2030 (USD Million)
  • Table 6 North America Retinal Vein Occlusion Treatment Market, by Country, 2018 - 2030 (USD Million)
  • Table 7 North America Retinal Vein Occlusion Treatment Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 8 North America Retinal Vein Occlusion Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 9 North America Retinal Vein Occlusion Treatment Market, by End-user, 2018 - 2030 (USD Million)
  • Table 10 U.S. Retinal Vein Occlusion Treatment Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 11 U.S. Retinal Vein Occlusion Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 12 U.S. Retinal Vein Occlusion Treatment Market, by End-user, 2018 - 2030 (USD Million)
  • Table 13 Canada Retinal Vein Occlusion Treatment Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 14 Canada Retinal Vein Occlusion Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 15 Canada Retinal Vein Occlusion Treatment Market, by End-user, 2018 - 2030 (USD Million)
  • Table 16 Europe Retinal Vein Occlusion Treatment Market, by Country, 2018 - 2030 (USD Million)
  • Table 17 Europe Retinal Vein Occlusion Treatment Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 18 Europe Retinal Vein Occlusion Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 19 Europe Retinal Vein Occlusion Treatment Market, by End-user, 2018 - 2030 (USD Million)
  • Table 20 Germany Retinal Vein Occlusion Treatment Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 21 Germany Retinal Vein Occlusion Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 22 Germany Retinal Vein Occlusion Treatment Market, by End-user, 2018 - 2030 (USD Million)
  • Table 23 UK Retinal Vein Occlusion Treatment Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 24 UK Retinal Vein Occlusion Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 25 UK Retinal Vein Occlusion Treatment Market, by End-user, 2018 - 2030 (USD Million)
  • Table 26 France Retinal Vein Occlusion Treatment Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 27 France Retinal Vein Occlusion Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 28 France Retinal Vein Occlusion Treatment Market, by End-user, 2018 - 2030 (USD Million)
  • Table 29 Italy Retinal Vein Occlusion Treatment Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 30 Italy Retinal Vein Occlusion Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 31 Italy Retinal Vein Occlusion Treatment Market, by End-user, 2018 - 2030 (USD Million)
  • Table 32 Spain Retinal Vein Occlusion Treatment Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 33 Spain Retinal Vein Occlusion Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 34 Spain Retinal Vein Occlusion Treatment Market, by End-user, 2018 - 2030 (USD Million)
  • Table 35 Denmark Retinal Vein Occlusion Treatment Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 36 Denmark Retinal Vein Occlusion Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 37 Denmark Retinal Vein Occlusion Treatment Market, by End-user, 2018 - 2030 (USD Million)
  • Table 38 Sweden Retinal Vein Occlusion Treatment Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 39 Sweden Retinal Vein Occlusion Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 40 Sweden Retinal Vein Occlusion Treatment Market, by End-user, 2018 - 2030 (USD Million)
  • Table 41 Norway Retinal Vein Occlusion Treatment Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 42 Norway Retinal Vein Occlusion Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 43 Norway Retinal Vein Occlusion Treatment Market, by End-user, 2018 - 2030 (USD Million)
  • Table 44 Asia Pacific Retinal Vein Occlusion Treatment Market, by Country, 2018 - 2030 (USD Million)
  • Table 45 Asia Pacific Retinal Vein Occlusion Treatment Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 46 Asia Pacific Retinal Vein Occlusion Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 47 Asia Pacific Retinal Vein Occlusion Treatment Market, by End-user, 2018 - 2030 (USD Million)
  • Table 48 China Retinal Vein Occlusion Treatment Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 49 China Retinal Vein Occlusion Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 50 China Retinal Vein Occlusion Treatment Market, by End-user, 2018 - 2030 (USD Million)
  • Table 51 Japan Retinal Vein Occlusion Treatment Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 52 Japan Retinal Vein Occlusion Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 53 Japan Retinal Vein Occlusion Treatment Market, by End-user, 2018 - 2030 (USD Million)
  • Table 54 India Retinal Vein Occlusion Treatment Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 55 India Retinal Vein Occlusion Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 56 India Retinal Vein Occlusion Treatment Market, by End-user, 2018 - 2030 (USD Million)
  • Table 57 South Korea Retinal Vein Occlusion Treatment Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 58 South Korea Retinal Vein Occlusion Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 59 South Korea Retinal Vein Occlusion Treatment Market, by End-user, 2018 - 2030 (USD Million)
  • Table 60 Australia Retinal Vein Occlusion Treatment Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 61 Australia Retinal Vein Occlusion Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 62 Australia Retinal Vein Occlusion Treatment Market, by End-user, 2018 - 2030 (USD Million)
  • Table 63 Thailand Retinal Vein Occlusion Treatment Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 64 Thailand Retinal Vein Occlusion Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 65 Thailand Retinal Vein Occlusion Treatment Market, by End-user, 2018 - 2030 (USD Million)
  • Table 66 Latin America Retinal Vein Occlusion Treatment Market, by Country, 2018 - 2030 (USD Million)
  • Table 67 Latin America Retinal Vein Occlusion Treatment Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 68 Latin America Retinal Vein Occlusion Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 69 Latin America Retinal Vein Occlusion Treatment Market, by End-user, 2018 - 2030 (USD Million)
  • Table 70 Brazil Retinal Vein Occlusion Treatment Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 71 Brazil Retinal Vein Occlusion Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 72 Brazil Retinal Vein Occlusion Treatment Market, by End-user, 2018 - 2030 (USD Million)
  • Table 73 Mexico Retinal Vein Occlusion Treatment Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 74 Mexico Retinal Vein Occlusion Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 75 Mexico Retinal Vein Occlusion Treatment Market, by End-user, 2018 - 2030 (USD Million)
  • Table 76 Argentina Retinal Vein Occlusion Treatment Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 77 Argentina Retinal Vein Occlusion Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 78 Argentina Retinal Vein Occlusion Treatment Market, by End-user, 2018 - 2030 (USD Million)
  • Table 79 Middle East & Africa Retinal Vein Occlusion Treatment Market, by Country, 2018 - 2030 (USD Million)
  • Table 80 Middle East & Africa Retinal Vein Occlusion Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 81 Middle East & Africa Retinal Vein Occlusion Treatment Market, by End-user, 2018 - 2030 (USD Million)
  • Table 82 Middle East & Africa Retinal Vein Occlusion Treatment Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 83 South Africa Retinal Vein Occlusion Treatment Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 84 South Africa Retinal Vein Occlusion Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 85 South Africa Retinal Vein Occlusion Treatment Market, by End-user, 2018 - 2030 (USD Million)
  • Table 86 Saudi Arabia Retinal Vein Occlusion Treatment Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 87 Saudi Arabia Retinal Vein Occlusion Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 88 Saudi Arabia Retinal Vein Occlusion Treatment Market, by End-user, 2018 - 2030 (USD Million)
  • Table 89 UAE Retinal Vein Occlusion Treatment Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 90 UAE Retinal Vein Occlusion Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 91 UAE Retinal Vein Occlusion Treatment Market, by End-user, 2018 - 2030 (USD Million)
  • Table 92 Kuwait Retinal Vein Occlusion Treatment Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 93 Kuwait Retinal Vein Occlusion Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 94 Kuwait Retinal Vein Occlusion Treatment Market, by End-user, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information Procurement
  • Fig. 3 Primary Research Pattern
  • Fig. 4 Market Research Approaches
  • Fig. 5 Value Chain-Based Sizing & Forecasting
  • Fig. 6 Market Formulation & Validation
  • Fig. 7 Retinal Vein Occlusion Treatment Market Segmentation
  • Fig. 8 Market Snapshot, 2022
  • Fig. 9 Market Trends & Outlook
  • Fig. 10 Market Driver Relevance Analysis (Current & Future Impact)
  • Fig. 11 Market Restraint Relevance Analysis (Current & Future Impact)
  • Fig. 12 PESTEL Analysis, By Factor (Political & Legal, Economic and Technological)
  • Fig. 13 Porter's Five Forces Analysis
  • Fig. 14 Global Retinal Vein Occlusion Treatment Market: Disease Type Movement Analysis
  • Fig. 15 Global Retinal Vein Occlusion Treatment Market, by Central Retinal Vein Occlusion (CRVO), 2018 - 2030 (USD Million)
  • Fig. 16 Global Retinal Vein Occlusion Treatment Market, by Branch Retinal Vein Occlusion (BRVO), 2018 - 2030 (USD Million)
  • Fig. 17 Global Retinal Vein Occlusion Treatment Market: Treatment Movement Analysis
  • Fig. 18 Global Retinal Vein Occlusion Treatment Market, by Anti-vascular Endothelial Growth Factor (Anti-VEGF), 2018 - 2030 (USD Million)
  • Fig. 19 Global Retinal Vein Occlusion Treatment Market, by Corticosteroid Drugs, 2018 - 2030 (USD Million)
  • Fig. 20 Global Retinal Vein Occlusion Treatment Market, by Others, 2018 - 2030 (USD Million)
  • Fig. 21 Global Retinal Vein Occlusion Treatment Market: End-user Movement Analysis
  • Fig. 22 Global Retinal Vein Occlusion Treatment Market, by Hospital & Clinics 2018 - 2030 (USD Million)
  • Fig. 23 Global Retinal Vein Occlusion Treatment Market, by Retail Pharmacy 2018 - 2030 (USD Million)
  • Fig. 24 Global Retinal Vein Occlusion Treatment Market, by Others, 2018 - 2030 (USD Million)
  • Fig. 25 Regional Marketplace: Key Takeaways
  • Fig. 26 Regional Outlook, 2022 & 2030
  • Fig. 27 Global Retinal Vein Occlusion Treatment Market: Region Movement Analysis
  • Fig. 28 North America Retinal Vein Occlusion Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 29 U.S. Retinal Vein Occlusion Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 30 Canada Retinal Vein Occlusion Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 31 Europe Retinal Vein Occlusion Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 32 Germany Retinal Vein Occlusion Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 33 UK Retinal Vein Occlusion Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 34 France Retinal Vein Occlusion Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 35 Italy Retinal Vein Occlusion Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 36 Spain Retinal Vein Occlusion Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 37 Denmark Retinal Vein Occlusion Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 38 Sweden Retinal Vein Occlusion Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 39 Norway Retinal Vein Occlusion Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 40 Asia Pacific Retinal Vein Occlusion Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 41 Japan Retinal Vein Occlusion Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 42 China Retinal Vein Occlusion Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 43 India Retinal Vein Occlusion Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 44 Australia Retinal Vein Occlusion Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 45 South Korea Retinal Vein Occlusion Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 46 Thailand Retinal Vein Occlusion Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 47 Latin America Retinal Vein Occlusion Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 48 Brazil Retinal Vein Occlusion Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 49 Mexico Retinal Vein Occlusion Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 50 Argentina Retinal Vein Occlusion Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 51 Middle East and Africa Retinal Vein Occlusion Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 52 South Africa Retinal Vein Occlusion Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 53 Saudi Arabia Retinal Vein Occlusion Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 54 UAE Retinal Vein Occlusion Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 55 Kuwait Retinal Vein Occlusion Treatment Market, 2018 - 2030 (USD Million)